- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.01. | TransCode Therapeutics regains compliance with Nasdaq | 2 | Seeking Alpha | ||
| 20.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | 75 | PR Newswire | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| 12.12.24 | Transcode Therapeutics stock hits 52-week low at $6.89 | 1 | Investing.com | ||
| 12.12.24 | Peering Into TransCode Therapeutics' Recent Short Interest | 1 | Benzinga.com | ||
| 06.12.24 | Transcode Therapeutics, Inc. - S-1, General form for registration of securities | 10 | SEC Filings | ||
| 02.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.12.24 | Why TransCode Therapeutics (RNAZ) Stock Is Diving | 3 | Benzinga.com | ||
| 02.12.24 | TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 | 2 | Seeking Alpha | ||
| 29.11.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split | 197 | GlobeNewswire (Europe) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
| 27.11.24 | TransCode Therapeutics announces $8M private offering | 2 | Seeking Alpha | ||
| 27.11.24 | TransCode Therapeutics, Inc. Announces $8 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 25.11.24 | Why Transcode Therapeutics (RNAZ) Stock Is Moving | 2 | Benzinga.com | ||
| 25.11.24 | TransCode Therapeutics to conduct reverse stock split | 14 | Seeking Alpha | ||
| 25.11.24 | TransCode Therapeutics approves reverse stock split | 3 | Investing.com | ||
| 25.11.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-33 Reverse Stock Split | 182 | GlobeNewswire (Europe) | BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
| 25.11.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
| 05.11.24 | TransCode Therapeutics maintains Nasdaq listing with conditions | 14 | Investing.com | ||
| 05.11.24 | TransCode Therapeutics gets Nasdaq extension to regain compliance | 8 | Seeking Alpha |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,935 | +0,65 % | Qiagen schüttet bis zu 300 Mio Dollar an Aktionäre aus | DJ Qiagen schüttet bis zu 300 Mio Dollar an Aktionäre aus
DOW JONES--Qiagen will über einen synthetischen Aktienrückkauf erneut bis zu 300 Millionen US-Dollar an seine Aktionäre ausschütten. Dabei... ► Artikel lesen | |
| NOVAVAX | 8,196 | +0,18 % | Looking Into Novavax's Recent Short Interest | ||
| MOLOGEN | - | - | EQS-News: Schutzgemeinschaft der Kapitalanleger e.V.: Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN A2DANN) mit Beständen bis zu 5.000 Euro Nominalwert können anteilige Vergütung des Gemeinsamen Vertreters zurückerhalten | Emittent / Herausgeber: Schutzgemeinschaft der Kapitalanleger e.V.
/ Schlagwort(e): Anleihe/Sonstiges
Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 1,040 | -0,19 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,980 | -2,94 % | Inovio Pharmaceuticals Prices $30 Mln Public Offering With Warrants | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,720 | -6,85 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| XOMA ROYALTY | 27,800 | +6,92 % | XOMA AB: Xoma collaborates with Professor Christiane Funk at Umeå University on the FLOW (Filtration of Liquids and Organic Waste) technology | ||
| PHIO PHARMACEUTICALS | 2,800 | -3,78 % | Phio-Aktie +290%: Beliebte SD-Kursrakete zündet erneut | Auch ein Winzling kann gigantische Renditen liefern: Mitten im aktuell schwierigen Umfeld für Biotech-Aktien ist am Montag die Aktie des Mini-Unternehmens Phio Pharmaceuticals um +290% auf 6,60 US$... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,273 | +7,91 % | T2 Biosystems, Inc. - 8-K, Current Report | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 8-K, Current Report | ||
| ORAGENICS | 0,276 | -4,83 % | ORAGENICS INC - 8-K, Current Report | ||
| LADRX | - | - | LadRx Corp - 10-Q, Quarterly Report | ||
| TENAX THERAPEUTICS | 2,770 | 0,00 % | Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative... ► Artikel lesen | |
| EDESA BIOTECH | 1,660 | +0,61 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal Year 2024 Results | TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,220 | -3,26 % | Windtree Therapeutics: Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline | WARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative... ► Artikel lesen |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,90 % bei einem Aktienkurs von 3,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.
